System Certification ISO 9001:2000
Exbio Antibodies CZ / SK eShop
by categories | a-z list | Application type: Flow Cytometry | Immunohistochemistry | Functional Studies

Mouse Monoclonal to CD263 / TRAIL-R3

TRAIL-R3-02 (IgG1)

Technical Information Request    Inquiry for Bulk Prices

Product No. Form Quantity Stock Price Datasheet Shop
  10-518-C025 azide free 0.025 mg yes choose region PDF datasheetHTML datasheet buy
  10-518-C100 azide free 0.1 mg yes choose region PDF datasheetHTML datasheet buy
  1F-518-C025 FITC 0.025 mg yes choose region PDF datasheetHTML datasheet buy
  1F-518-C100 FITC 0.1 mg yes choose region PDF datasheetHTML datasheet buy
  1P-518-C025 PE 0.025 mg yes choose region PDF datasheetHTML datasheet buy
  1P-518-C100 PE 0.1 mg yes choose region PDF datasheetHTML datasheet buy
- In stock! Ready for immediate despatch - Manufacture on order


TRAIL-R3 (CD263, TR3, DcR1, LIT, TRID), expressed mainly on neutrophils, belongs to receptors of TRAIL, a TNF-like membrane cytotoxic protein that induces apoptosis in many tumour cells, but not in normal cells. TRAIL-R3, however, is a GPI-anchored protein that lacks cytoplasmic death domain, thus it is unable to induce apoptosis and serves as a negative regulator of apoptotic signaling by competing for binding of TRAIL with death receptor 5 (DR5).


The antibody TRAIL-R3-02 reacts with TRAIL-R3, a 35 kDa GPI-anchored extracellular membrane protein expressed mainly on neutrophils.

Regulatory Status


TRAIL-R3 (aa 1-280) - hIgGhc fusion protein

Species Reactivity:

  • Human

Negative Species:


  • Flow Cytometry
    Recommended dilution:1-5 μg/ml
Usage note:
Indicated dilutions are recommended starting points for use of this product. Working concentrations should be determined by the investigator.

General references

  • *Clancy L, Mruk K, Archer K, Woelfel M, Mongkolsapaya J, Screaton G, Lenardo MJ, Chan FK: Preligand assembly domain-mediated ligand-independent association between TRAIL receptor 4 (TR4) and TR2 regulates TRAIL-induced apoptosis. Proc Natl Acad Sci U S A. 2005 Dec 13;102(50):18099-104. [Abstract] [Full Text]
  • *Sanlioglu AD, Dirice E, Aydin C, Erin N, Koksoy S, Sanlioglu S. Surface TRAIL decoy receptor-4 expression is correlated with TRAIL resistance in MCF7 breast cancer cells. BMC Cancer. 2005 May 25;5(1):54. [Abstract] [Full Text]
  • *Mérino D, Lalaoui N, Morizot A, Schneider P, Solary E, Micheau O: Differential inhibition of TRAIL-mediated DR5-DISC formation by decoy receptors 1 and 2. Mol Cell Biol. 2006 Oct;26(19):7046-55. [Abstract] [Full Text]
  • *Falschlehner C, Emmerich CH, Gerlach B, Walczak H: TRAIL signalling: decisions between life and death. Int J Biochem Cell Biol. 2007;39(7-8):1462-75. [Abstract]
  • *Deligezer U, Dalay N: Expression of the TRAIL Receptors in Blood Mononuclear Cells in Leukemia. Pathol Oncol Res. 2007;13(4):290-4. [Abstract]
  • For research use only. Not for drug, diagnostic or other use.

    Example Data

    Unless indicated otherwise, all products are For Research Use Only and not for diagnostic or therapeutic use. Not for resale or transfer either as a stand-alone product or as a component of another product without written consent of EXBIO. EXBIO will not be held responsible for patent infringement or other violations that may occur with the use of our products. All orders are accepted subject to EXBIO´s term and conditions which are available at
    © 2003 EXBIO. All rights reserved.
    terms and conditions | privacy policy